We have completed the phase I portion of the clinical study evaluating the safety and toxicity of vandetanib combined with bortezomib in patients with advanced malignancies. The drug combination appears to be safe and we have embarked on the phase II portion of the study, which is a 2:1 randomization comparing the drug combination to vandetanib alone in the treatmet of patients with advanced MTC. We have not studied enough patients to tell if the combination is superior to vandetanib alone These studies are important because chemotherapy and radiotherapy are ineffective in patients with advanced MTC. We have recently showed that vandetanib is effective in patients with metastatic MTC. Based on the study the FDA approved the compound for the treatment of patients with advanced MTC. In the current and future studies we seek to show that new agents are more efficacious than vandetanib in the treatment of advanced MTC, especially when used in combinations, which based on preclinical studies, are shown to be more effective than single agent therapy. There is also no effective therapy for patients with anaplastic thyroid carcinoma and we hope to show that the phase I/II trial of crolibulin (EPC2407) plus cisplatin in adults with solid tumors with a focus on anaplastic thyroid cancer will show efficiacy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC011389-01
Application #
8349515
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2011
Total Cost
$232,325
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code